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SUMMARY
The involvement o f  proteases in the metastatic spread o f  tumour cells and in tumour 
related processes, such as angiogenesis and ulceration> has been known for many 
decades. This chapter reviews the involvement o f one proteolytic systein -  the plas­
minogen activation system -  in tumour progression. In recent years, many biochem­
ical properties o f the various components o f  the plasminogen activation system have 
become know n . These properties and the functional relationship between the com­
ponents are discussed in the first section. Since interfering with proteolysis by tumour 
cells and by newly formed endothelial cells can be an objective for future therapy, 
experimental tumour models have been used to study the effects of  inhibitors o f plas­
minogen activation. The second section deals tuith this issue. Finally, the presence o f  
the various components o f the plasminogen activation system in human tumours is 
reviewed. Following the availability o f specific ELlSAs, antibodies and molecular 
probes, the content and the cellular distribution o f  the components o f  the plasmino­
gen activation system have recently been mapped in various human tumours.
Basic Properties of the Components of the 
Plasminogen Activation System
The plasminogen activation system consists of two 
plasminogen activators, tissue-type plasminogen acti­
vator (t-PA), and urokinase-type plasminogen activa­
tor (u-PA), which convert plasminogen into the 
active zymogen plasmin. u-PA can bind to a specific 
receptor, u-PAR. Several plasminogen activator inhibi­
tors have been described, of which two (PAI-1 and 
PAI-2) will be reviewed here. The basic properties will 
be mentioned briefly, and the interrelationship between 
the components u-PA, u-PAR and PAI is outlined. Also, 
the involvement of these components in experimental 
models for tumour invasion and metastasis and their 
presence in human tumours are considered.
Plasminogen Activators t-PA and u-PA
t-PA and u-PA are produced as single serine proteases 
and can be converted to two-chain proteases upon 
cleavage by plasmin. The two-chain forms of plasmino­
gen activators are held together by a disulfide bridge. 
Both single chain and two-chain t-PA are enzymati­
cally active. Single chain u-PA (pro-u-PA), however, 
is inactive and can be converted to active two-chain 
u-PA upon binding to the cell surface receptor u~ 
PAR. Structural characteristics for both t-PA and u~ 
PA are a) similarities in the serine protease domain 
and b) the presence of kringle domains (t-PA has 
two, u-PA has one). (Pro-)u-PA contains a growth fac­
tor domain, necessary for binding to u~PAR (see 
also200*217).
Apart from structural differences, t-PA and u-PA dif­
fer in their presumed (patho-) physiological functions. 
t-PA mainly plays a role in fibrinolysis: t-PA specifically
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binds to fibrin. t-PA is also the plasminogen activator of 
the adult brain195 and is thought to play a role in plas­
ticity and long term memory™. Also, t-PA is expressed 
by oocytes192 whereas u-PA is expressed by spermato­
cytes82. u-PA, but also t-PA, are involved in wound 
healing67,I78. Compared to t-PA, u-PA is thought to 
play a more dominant role in tissue remodeling pro­
cesses such as spermatogenesis83, trophoblast inva­
sion192, wound healing67, monocyte invasion96 and 
angiogenesis5, l5B, often together with u-PAR160’182 
and PAI5,159. u-PA is the predominant plasminogen ac­
tivator involved in tumour invasive processes and me­
tastasis.
melanomas, plasminogen is localized in stromal cells 
at the invasive front and in extracellular matrix (De 
Vries et al., J. of PathoL, 1996, in press). Specific in­
hibitors of plasmin activity, a 2-macroglobulin122 and 
a z-antiplasmin21 are found both in (normal) plasma 
and in tumour tissues. Recently, it was described that 
a plasminogen fragment containing the kringle 1 -3  
domains, named angiostatin, is capable of inhibiting 
tumour angiogenesis148.
Urokinase-mediated Plasminogen Activation at the
Cell Surface
Urokinase Receptor u-PAR
Pro-u-PA can bind to cells via u-PAR, the cell surface 
receptor for u-PA11,222. u-PAR consists of three do­
mains and is linked to the membrane via a glycosyl- 
phosphatidylinositol anchor. u-PAR plays a role in 
plasminogen activation at the cell surface.
Plasminogen Activator Inhibitors PAI-1 and PAI-2
The two plasminogen activator inhibitors focused on 
in this chapter, PAI-1 and PAI-2, belong to the group of 
serpins: serine protease inhibitors. Other PAIs are PAI- 
3 and protease-nexin. Both PAI-’l and PAI-2 are ca­
pable of inhibiting t-PA and u-PA (reviewed in108,202) 
.H it do not bind to pro-u-PA1.
PAH is found in high concentrations in the blood, 
where it plays a role in fibrinolysis. Uncomplexed 
PAI-1 becomes rapidly latent due to its instability133. 
PAI-1 is secreted and sticks extracellularly to vitronec­
tin70*106. PAI-2 is found in placental tissue54,79 and in 
the blood of pregnant women4. Unlike PAM, PAI-2 is 
not secreted into the extracellular matrix and is loca­
lized mainly in the cytoplasm8.
Plasminogen
Plasminogen is the substrate for plasminogen activa­
tors, Cleavage of plasminogen by plasminogen activa­
tors forms the active enzyme plasmin. Plasminogen
s to various proteins of the extracellular matrix, 
like fibronectin1 , laminin189, type IV collagen205 
and to tetranectin32, Plasmin is capable of degrading 
a broad spectrum of matrix molecules. Furthermore, 
plasmin can convert inactive pro-collagenases into 
the active form. Plasmin/plasminogen binds to the cell 
surface of MCF7 cells36,241, but a receptor for plasmin 
has not been cloned. It has been reported that binding 
of plasminogen to cell surfaces occurs in the proximity
of binding sites for t-PA (Felez 1993) or u-PA241.
Little is known about the presence of plasmin/plas­
minogen in cancerous tissues. In colon carcinomas, it is 
reported to be present in stromal cells21,229. Also in
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u-PA activity can be focalized on the cell surface by 
binding to u-PAR11*207. Moreover, u-PA activity can be 
modulated by interaction of u-PA with its receptor: 
binding to the receptor accelerates the conversion of 
pro-u-PA to active u-PA on the cell surface50,177, pos- 
sibly by close interaction with the receptor bound plas- 
m in126,206. Binding of pro-u-PA to u-PAR is facilitated 
when u-PAR is glycosyl-phosphatidylinositol an­
chored131 and when the ligand binding site of u-PAR 
is glycosylated132. Upon binding to u-PAR, pro-u-PA 
is converted to active u-PA after cleavage by plasmin 
or cathepsins97. The active enzyme complex, in close 
proximity of plasmin/plasminogen241 can convert plas­
minogen to plasmin, a broad substraste protease ca­
pable of degrading various components of the 
extracellular matrix. u-PA bound to u-PAR is essential 
for migration of monocytes96 and tumour cells17,203. In 
migrating cells, u-PAR is concentrated at the ruffled 
edge of cells6 and in caveolae204. Caveolae, which 
are in the proximity of focal adhesion sites, are essen­
tial for u-PA mediated proteolysis at the cell surface,
le specific caveolar structures 
abolish plasminogen activation204. u-PA163 and u- 
PAR137 are both expressed at focal cell-cell or cell-sub- 
strate adhesion sites. This concentration of proteases at 
focal adhesion sites suggests that a delicate balance ex­
ists between adhesion and proteolysis (see also103). In­
deed, adhesion molecules are found to co-localize with 
u-PA and u-PAR: both u-PA and u-PAR co-localize with 
a vp3 in cultured glioblastomas63, and u-PAR co-loca- 
lizes with a vp3 in metastatic melanoma cells143. 
Furthermore, u-PAR is found in the same membrane 
fragments as (J2-integrins1,\  In cultured keratino- 
cytes, u-PA co- ocalizes with another adhesion mole­
cule, E-Cadherin93. The delicate balance between 
adhesion and local proteolysis can be shifted towards 
u-PA production and invasion when adhesion is ham­
pered, for instance by an antibody capable of blocking 
ligand binging of the adhesion molecule60. In light of 
the delicate balance between adhesion and local pro­
teolysis, it is very interesting that u-PAR can perform 
both functions. u-PAR not only focalizes proteolysis 
at the cell surface by binding pro-u-PA, unoccupied 
u-PAR can also function as an adhesion molecule for 
vitronectin224,228. Furthermore, binding of u-PA to u- 
PAR can start a signal transduction pathway, since cy-
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Fig. 1. A model for plasminogen activation at the cell surface. 
The sequential events at the cell surface are depicted from left 
to right in this diagram. Pro-u-PA binds to free u-PAR, and is 
activated through cleaveage by plasmin or cathepsins (not 
shown in this diagram). The activated u-PA can convert plas­
minogen to plasmin and can be inhibited by PAL The u- 
PAR:u-PA:PAI-complex is efficiently bound and internalized 
by LRP. Upon internalization, u-PA and PAI are degraded and 
u-PAR is recycled to the cell surface. See text for details.
tokeratin 8 is phosphorylated upon binding, resulting 
in phosphorylation and redistribution of cytokeratin 
filaments in human epithelial cells21* Protein tyrosine 
kinases are localized in the same membrane receptor 
complex as u-PAR13.
Active u-PA bound to u-PAR can be inactivated by 
PAL The u~PAR;u-PA:PAI complex, especially the u- 
PA:PAI part145, is recognized by LRP. The complex 
of u-PAR:u-PA:PAI:LRP can be internalized via a cla- 
thrin coated pit mechanism. u-PA and PAI are degraded 
in lysosomes and LRP and u-PAR are redistributed to 
the plasma membrane39,52,78. Figure 1 shows the se­
quential events, proposed to take place at the cell sur­
face.
Proteins Related to the Plasminogen Activation 
Process
Proteins recently described as related to the PA sys­
tem are the plasminogen binding protein tetranectin 
and members of the LDL receptor family, enabling in­
ternalization of (inactivated complexes of) plasmino­
gen activators.
Tetranectin
Tetranectin is a 68 kD protein that was purified from 
plasma and binds to the feringle 4 domain of plasmino­
gen32. Plasma of cancer patients contains significantly 
lower levels of tetranectin compared to age and sex
matched control groups80’91,141. Tetranectin is present 
in a variety of cells, including monocytes142, neutro­
phils14 and fibroblasts33. In breast31, ovarian80 and co­
lon223’229 carcinomas, and in melanomas (De Vries et 
al., manuscript in prepation), tetranectin is present in 
the stroma surrounding the tumour Moreover, plasma 
tetranectin content and stromal immunoreactivity are
a ^  m
cer
LRP and RAP
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Two proteins involved in the clearence and cellular 
uptake of inactivated proteases are the low density 
lipoprotein receptor-related protein (LRP)/a2-macro- 
globulin receptor(a2MR) and its receptor associated
protein (RAP).
LRP is a member of the LDL receptor family107,209. 
LRP/a2MR is named after its homology with the low 
density lipoprotein receptor76 and after its capability 
to bind the activated forms of a 2-macroglobulin3. 
The gene encoding the enormous protein comprises
89 exons221, revealing a 15 kb mRNA transcript, from 
which a 600 kD precursor protein is translated which is 
cleaved into a 515 kD a-chain and an 85 kD p-chain. In 
addition to activated complexes of a 2-macroglobulin, 
many other ligands can be internalized upon binding 
to LRP, including ApoE and various proteins or com­
plexes of proteins of the plasminogen activation system 
(reviewed in2). t-PA can bind to LRP18 and complexes 
of t-PA with PAI-1 can be internalized mediated by 
LRP149. LRP-mediated internalization of complexes 
of u-PA with inhibitors occurs most efficiently when 
u-PA is bound to its receptor34»78»145. Gp330 (= 
gp600), another member of the LDL receptor family, 
is also capable of internalizing similar ligands as 
LRP, including plasminogen activators231.
RAP is a 39 kDa protein which co-purifies with LRP 
and other members of the LDL receptor family208 and 
co-localizes with LRP20, 242, RAP is restricted to the 
endoplasmatic reticulum and serves as a chaperone 
for LRP20’232. RAP can bind to LRP and thereby pre­
vent binding of all other known ligands, including 
(complexes of) plasminogen activators77,86»144,226.
Little is known about LRP and RAP expression in 
human tumor cell lines or in human tumors. In human 
tumour cell lines, it seems that LRP expression de­
creases with agressiveness because a) tumor cells make 
no or less receptor for a 2-macroglobulin when com­
pared to non-tumor cell lines92’187“189’220, b) mono­
cytes grown without the tumor promotor PMA start 
making LRP35, c) LRP is present in photodynamic ther­
apy sensitive tumor cells and not in therapy resistant 
cells118 and d) invasive cells make less LRP than 
non-invasive cells94. In human tumors, LRP has been 
detected in blood samples of monocyte-derived malig­
nant blood cells and not in other hematologic tumour 
cells128, it is present in glioma cells117, and is decreased
or absent in malignant lymphomas129 and in hepatocel­
lular carcinomas64.
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Plasminogen Activation in Experimental Models for
Tumour Invasion and Metastasis
The process of metastasis is a complex multistep pro­
cess involving detachment of tumour cells from the pri­
mary tumour, invasion of surrounding host tissue, 
invasion through basal membranes, intravasation into 
the circulatory system, adherance to endothelium or 
subendothelial basement membrane and extravasa­
tion at a distant site and outgrowth of a secondary tu­
mour56. A role for proteases has been postulated in 
various steps of this process4 0 , 1 6 4 >2i 9t First, in­
vading tumour cells need proteases to degrade the sur­
rounding tissue and extracellular matrix, and secondly, 
proteases are required for intravasation and extravasa­
tion.
Various in vitro and in vivo model systems have been 
developed which can be employed to study and manip­
ulate various aspects of the complex process of meta­
static spread. Matrix degradation assays can be used to 
study the activity of proteases176,177. Invasion assays, 
either employing reconstituted matrix154 or chicken 
membranes151,153, or human placenta membranes124 
or chick heart119, can be used to study true invasion 
of tumour cells. Finally, immunodeficient mice can 
be used to study experimental metastasis by injecting 
tumour cells in the tail vein98,99,150> 176, or, to study 
spontaneous metastasis, from a tumour grown upon 
injecting tumour cells subcutaneously98*99,176,
Figure 1 illustrates that if the plasminogen activation 
system is indeed crucial in invasive processes and in 
metastasic spread of tumour cells, effects of interfer­
ence could prove this at two places in this process. 
By preventing pro-u-PA to bind to u-PAR, no cell sur­
face plasminogen activation can take place (Fig. 2a). 
Also, anti-catalytical substances such as anti-u-PA anti­
bodies, exogenously added PAI and chemical sub­
stances binding to the catalytical domain of u-PA 
can prevent plasminogen activation (Fig. 2b).
Disturbance of pro-u-PA binding can be achieved by 
molecules which can compete for the pro-u-PA binding 
site of u-PAR (Fig. 2a). Blocking the pro-u-PA binding 
site with an anti-u-PAR antibody demonstrated that 
cell surface plasminogen activation can be abol­
ished183. Glioblastoma cells thus treated are less inva­
sive in matrigel130. Also, cells of which u-PAR is 
saturated with the amino terminal fragment (ATF) of 
u-PA (e.g. not containing the catalytical site) are less 
invasive in matrigel98. Synthetic peptides comprising 
the binding domain of u-PA are able to inhibit sponta­
neous metastasis formation in a nude mouse metastasis 
model99. A most dramatic reduction of metastasis for­
mation from a tumour, by preventing pro-u-PA to bind 
to its receptor, has been shown by Crowley and co­
workers38. By transfecting u-PA and u-PAR producing 
tumour cells with ATF, an enormous reduction of me­
tastasis formation could be achieved. Smaller chemical 
substances can prevent pro-u-PA binding. Low doses of 
suramin, for instance, prevent cell surface binding of u- 
PA7. Also small 15-mer peptides could be identified as
V
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Fig. 2. Prevention of u-PA mediated plasminogen activation. 
Invasive properties of tumor cells can be reduced by interven­
tion of the plasminogen activation system. This can be 
achieved by either of two ways: a) by preventing pro-u-PA 
to bind to u-PAR, or b) by blocking the active site of active 
u-PA (b). A: Preventing pro-u-PA to bind to u-PAR. Invasive 
properties can be inhibited by preventing pro-u-PA to bind to 
its receptor. This can be achieved either by blocking the recep­
tor with antibodies or with (truncated) molecules which block 
the u-PA binding site of u-PAR, or by competing with soluble 
forms of u-PAR. B: Blocking the active site of u-PA. Active u- 
PA can be inhibited by anti-catalytic antibodies, by endoge­
nous or exogenously added PAI, or by chemical substances 
which block the catalytic domain. See text for details.
u-PAR antagonists65. Apart from blocking the cell sur­
face u-PAR, pro-u-PA binding can be competed with a 
soluble form of u-PAR, thereby preventing pro-u-PA to 
bind to its cell surface receptor. Addition of the soluble 
form of u-PAR to u-PA and u-PAR positive tumour cells 
can indeed inhibit invasion230. In summary, invasive 
properties of tumour cells can be reduced by interfer­
ence with u-PA:u-PAR binding. This may lead to
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new therapeutic approaches in the near future 
(reviewed in53). u-PA conjugated to a cytotoxic agent 
can be used to specifically destroy u-PAR positive
ceils29.
The first evidence, however, that the plasminogen 
activation system is involved in tumour invasive and 
metastatic processes, arose from experiments designed 
to block the active u-PA (Fig. 2b). Antibodies blocking 
the catalytic site of u-PA do not block tumour growth, 
but can inhibit metastasis formation73,81,150. Also, in­
vasive properties of tumour cells can be reduced when 
they are pretreated with anti-catalytic antibodies 
against u-PA124,151. Matrix degradation of u-PA posi­
tive tumour cells is reduced when tumour cells are pre­
treated with anti u-PA antibodies 180. In addition to 
anti-catalytic antibodies, the catalytic domain of u-PA 
can be blocked with PAI-1 or PAI-2. PAM or PAI-2 
added to cultures of u-PA and u-PAR positive cells ef­
fectively inhibits matrix degradation180. Furthermore, 
HT1080 fibrosarcoma cells producing a surplus of 
PAI-2 are less invasive112 and melanoma cells trans­
fected with PAI-2 give rise to significantly less metas- 
tases in nude mice134. Smaller organic chemical 
substances like benzo (b) thiophene-2-carboxami- 
dines218 and low doses of suramin52,211 can specifi­
cally inhibit u-PA.
Inhibition of invasion and metastasis formation can 
also be obtained by reducing the amount of u-PAR 
available at the cell surface. Tumour cells transfected 
with antisense u-PAR are less tumourigenic and less 
invasive105»174. B16 melanoma cells transfected with 
the antisense construct of u-PA make fewer metas- 
tases240.
The other way around, actively invading and metas­
tasizing cells can be generated by overexpressing u~ 
PAR95 or by overexpressing u-PA240. In general, cell 
lines expressing high levels of u-PA are more invasive 
than cell lines expressing low levels of u-PA16,75.
All the above described experiments suggest a role 
for the plasminogen activation system in tumour inva­
sion and metastasis. The simultaneous presence of not 
only u-PA and u-PAR but also of PAI in highly meta­
static melanoma cells176, the required presence of u- 
PA> u-PAR and PAI-1 in highly invasive lung cancer 
cells116, and elevated levels of u-PA, u-PAR and PAI
-  simultaneously present in the same lesion44,49»179 -  
in human tumours suggests that a subtle balance of re­
ceptor, protease and inhibitor is required for effective 
invasiveness of tumour cells.
The Plasminogen Activation System in Human
Tumours
Proof that the plasminogen activation system plays a 
role in tumour invasion and metastasis not only stems 
from experimental evidence, but also from direct evi­
dence in human tumours. Elevated levels of u-PA, u- 
PAR and PAI-1 compared to normal tissues are consis­
tently found in different tumours (e.g.23’42»44’63*198). 
Elevated levels of t-PA42’44,109,121 and PAI-244,45,198
are found in some tumours, but an inverse relationship 
(lower levels in tumour tissue compared to the normal 
tissue) often exists for t-PA198,237,and PAI-215,58,21l). 
Techniques with which the presence and the localiza­
tion of the components of the plasminogen activation 
system have been studied in human tumours are ELISA, 
immunohistochemistry and RNA in situ hybridization. 
With zymographic techniques, enzyme activity of t-PA 
and u-PA can be studied either in frozen tissue sections 
or in gels upon electrophoretic separation of the en­
zymes.
ELISA Determinations
When larger tumours are available, ELISAs specific 
for the various components can be performed on tissue 
extracts of these tumours. The level of u-PA, but also of 
PAI-1 and u-PAR has been shown to be of prognostic 
relevance. For breast cancer, for instance, the level of u- 
PA and PALI surpasses prognostic parameters for re­
lapse of the disease used so far, including lymph node 
involvement and estrogen receptor status46’47,57,69, 
87,90. High levels of both u-PA and PAI-1 are also asso­
ciated with poor survival in patients with colorectal 
cancer61, gastric cancer140, uterine cervical cancer100 
and lung cancer155,156. After the first report on the 
prognostic relevance of u-PAR by Ganesh and co- 
workers62 in colorectal cancer, high u-PAR levels were 
also found to be associated with poor survival in pa­
tients with breast cancer49,185 and squamous and large 
cell lung cancer156.
In addition to tumour homogenates, elevated levels 
of components of the plasminogen activation system 
were reported in body fluids such as tumour ascites 
and plasma. Huber et al. detected elevated levels of 
u-PA in plasma of patients with colorectal cancer85 
and in patients with primary liver cancer84 and found 
that the u-PA value in combination with tumour mar­
ker measurement, contributed to the sensitivity of the 
diagnosis. High levels of a soluble form of u-PAR157, u- 
PA, PAI-130 and of PAI-230,113 have been detected in 
ascites of patients with ovarian cancer.
Immunohistochemistry and mRNA in situ
Hybridization
The cellular distribution of the mRNAs and the pro­
teins can be studied with mRNA in situ hybridization 
(e.g,42,44’63,167, 168,193) and with immunohistochemis­
try (e.g.44,45,68,127), respectively. From recent litera­
ture, it is evident that the components of the 
plasminogen activation system are localized in tumour 
cells and in various tumourassociated cell types, prob­
ably depending on the tumour studied. For instance, u~ 
PA mRNA and protein is reported to be present in tu­
mour surrounding fibroblasts in colon cancer68,167, 
whereas u-PA is localized in tumour cells42,44 and fibro­
blasts44 in cutaneous melanoma, and in tumour cells in 
squamous cell carcinoma127, 193. The presence of the 
serine proteases in the tumour stroma is a phenomen­
on also reported for other proteases. Metalloproteases
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for instance, primarily localize in the stroma of tu­
mours136,147,1^ 9,233. The system may function in an 
autocrine way, e.g. through saturation of u-PAR by tu­
mour cells207. Also, paracrine mechanisms acting be­
tween u-PA producing stroma cells and u-PAR 
positive tumour cells can occur (reviewed in12). In­
deed, it has been shown in in vitro experiments that 
matrix degradation177 and invasion152 is facilitated 
when u-PA positive cells are mixed with u-PAR posi­
tive cells. Similar cooperative interactions could occur 
in colon cancer, where u-PAR positive tumour cells bor­
dering u-PA positive stroma cells could pick up u-PA 
from these stroma cells167. Other paracrine interac­
tions between tumour cells and fibroblasts are in agree­
ment with many reports suggesting that fibroblasts 
facilitate invasion186 and metastasis formation161’216. 
Furthermore, it has been reported that fibroblasts in 
tumour cell-fibroblast co-cultures are capable of indu­
cing the production of u-PA and metalloprotei- 
nases37,114.
Reports on the localization of the various compo­
nents in any particular tumour type are not unani­
mous. For instance, u-PA protein has been found in 
some reports in colon cancer exclusively in fibroblastic 
cells68,2^ 3, but also mainly in tumour cells135* 197. Like­
wise, u-PA localization has been reported in tumour 
cells87’90, but also exclusively in fibroblastic cells233 
in mammary carcinoma.
(in situ) Zymography
Plasminogen activator activity can be detected either 
in a frozen section (in situ zymography)42,44,45, 193, 194 
or in electrophoresis gels in tissue homogenates, the 
latter technique allowing visualization of enzymatic ac­
tivity of plasminogen activators complexed with 
PA *201. t-PA and u-PA can be distinquished through 
anti-catalytic antibodies anti-t-PA or u-PA, or by add­
ing specific t-PA or u-PA inhibitors.
t-PA in Human Tumours
When comparing the two types of plasminogen activa­
tors with respect to their putative role in human tumours, 
u-PA seems to be the most important plasminogen acti­
vator, since levels of t-PAare often either undetectable127, 
similar210 or lower23*61,138,166, 198>201 in tumour tissue 
compared to corresponding normal or benign tissue. 
Also, primary cultures of tumours210 and tumour cell 
lines1™ predominantly produce u-PA. In contrast to t-
PA,u-PAisconsistentlyincreasedineverytumoui\Never-
theless, t-PA levels in tumour homogenates can be of par­
ticular prognostic interest, Yamashita et al. found that 
disease-free breast cancer patients had significantly low­
er levels of t-PA in the tumour, than patients which devel­
oped metastases238. Also, a low level of t-PA in colon 
cancer, but now in the normal mucosa, is associated with 
poor prognosis61.
With regard to decreased t-PA expression in human 
tumours, melanoma is an interesting exception. Firstly,
t-PA can be isolated from cultured melanoma cells181. 
In vitro, melanomas make more t-PA than other tu­
m ours175,176, enabling the cells to degrade extracellu­
lar m atrix176 and to migrate through reconstituted 
m atrix123* Secondly, malignant melanomas and not be­
nign nevi express t-PA42,44,109 (see also Fig. 3a). In 
uveal melanomas, t-PA is found more abundantly in 
tumours with less favorable prognosis45. Higher levels 
of t-PA have been reported in carcinoma of the cervix 
by Larsson et al.111. t-PA has been found in endothelial 
cells in benign precursor and in tumour lesions23,44s 101, 
consistent with a role for t-PA in fibrinolysis.
u-PA in Human Tumours
Of the various proteins of the plasminogen activa­
tion system, u-PA has been studied most intensely in 
human malignancies (reviewed in48). u-PA levels of tu­
mour homogenates have been found of prognostic sig­
nificance for various types of tumours.
The presence of u-Pa in colon cancer has been well 
documented. Controversy exists on where the protein
is localized. It has been claimed that u-PA is localized in 
tumour ceiisioi,io2,i35,i97^ Others found u-PA
mRNA167 and protein exclusively68, or mainly213, in 
the tumour stroma. Significant for the localization 
of u-PA and for its possible implications for meta­
static spread, is the finding by Tan213 that invasive 
parts of a tumour are u-PA positive, in contrast 
to pushing edges which hardly displayed u-PA positiv- 
ity. On paraffin sections, Mulcahy et al.135 found that 
tumour cell associated u-PA and not stromal cell 
associated u-PA is of prognostic relevance. Also for 
the u-PA/t-PA ratio a prognostic significance has been 
reported in colon carcinomas61. In addition, patients 
with colon carcinomas exhibit higher levels of u-PA 
in plasma85.
In breast cancer, the level of u-PA measured in tu­
mour extracts is a prognostic indicator for relapse of 
the disease15,47j 57>87“89, reviewed in196. Janicke et al. 
could correlate intensity of u-PA tumour cell staining 
to ELISA values measured in parallel samples87. 
Others also found u-PA in mammary carcinomas loca­
lized in tumour cells28,90.
In brain tumours, u-PA is detectable in high grade 
astrocytomas and gliomas23,63, 110,235. u-PA 
mRNA63,235 and protein2* 235 localize in tumour cells 
and in the frustrated vasculature, characteristic for 
these lesions.
Carcinomas of the oesophagus and the stomach con­
sistently exhibit higher u-PA levels compared to the 
normal surrounding tissue139’199. Furthermore, in gas­
tric carcinomas, u-PA staining of tissue sections74 and 
u-PA values of tum our homogenates140 yield prognos- 
tically useful information.
in bladder cancer, higher levels of u-PA is correlated 
with recurrent disease71,72.
u-PA is detectable in tumour cells of various types of 
lung cancer66, 146. Levels of u-PA are significantly high-
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er in these tumours compared to normal lung tissue138 
and are of prognostic importance155-156.
In skin cancers, u-PA is not expressed in basal cell 
carcinomas, but is expressed in squamous cell carcino­
mas127, 193. Human cutaneous melanomas exhibit u-PA 
activity and immunoreactivity only in the primary tu­
mours and métastasés42,44,1215 whereas u-PA mRNA 
can also be detected in atypical nevi42. In melano­
mas, the protein is present in a minority of the tumour 
cells at the invasive front42,44 (see also Fig. 3d) and in 
stromal cells at the edge of the tumour44 (see also 
Fig. 3e). In uveal melanomas, u-PA is present in tu­
mours with worse prognosis and in metastatic le­
sions45. Stromal u-PA staining has also been reported 
in cervical cancer of the uterus100,111. Patients with 
lymph node involvement exhibited more prominent 
u-PA staining and higher antigen values in the primary 
tumour compared to tumours of patients without 
lymph node involvement100.
Abundant u-PA activity is found in mononuclear 
cells of leukemia patients. These high levels of u-PA 
could contribute to bleeding disorders, often found 
in patients with leukemia216.
u-PAR in Human Tumours
A role for u-PAR in tumour development has recently 
been described by Dan0  et al.41. Specific ELIS As for u- 
PAR Have only recently been developed and used to 
study the levels of u-PAR in human tumour tis­
sues62’ 184. Initial studies report that high u-PAR levels 
are associated with poor survival in colon cancer62, in 
squamous cell and large cell lung cancer157, and breast 
cancer49.
Limited visualization of u-PAR in immunohisto- 
chemistry can be due to masking of epitopes, due to 
u-PA bound to u-PAR. u-PA can be released from its 
receptor by mild acid treatment of the tissue section, 
and a much brighter u-PAR staining can thus be ob­
tained28,43. Free u-PAR can further be visualized with 
autoradiography after incubation with radioactive u- 
PA to the cells or tissues of interest43,225.
The distribution of u-PAR mRNA and protein has 
been studied most extensively in tumours of the mam­
mary gland10,28,43’90,170. u-PAR mRNA is produced 
mainly by tumour associated macrophages170, but it 
has also been reported that the protein is predomi­
nantly present in tumour cells10,28,43s90? in addition 
to tumour-associated macrophages10. In colon can­
cer, u-PAR mRNA and protein is present in macro­
phages and tumour cells167,172, possibly basally 
expressed by tumour cells towards the stroma225. In 
astrocytomas, u-PAR mRNA is expressed by prolifer­
ating vessels and by tumour cells in the vicinity236. 
Also in gliomas, u-PAR is expressed by tumour 
cells63. In melanomas, u-PAR has mainly been found 
in tumour cells (Fig. 3b), though also in fibroblastic 
cells44,4S. It has been reported for ovarian cancer how­
ever, that u-PAR is already present in the normal epithe­
lium239. Surprizing, and not consistent with a general 
rule that levels of u-PAR are elevated in cancer, is 
the absence or the reduced presence of u-PAR in all 
B- and T-cell malignancies and in Hodgkin’s disease162.
PAI-1 in Human Tumours
It has been postulated that high levels of PAI in can­
cer tissue, might be beneficial for the patient, since a 
surplus of PAI might inactivate all plasminogen activa­
tors present. Apart from a rare report of decreased PAI-
1 in more aggressive versus less aggressive tumours66, 
PAI-1 levels are consistently increased in tumours of 
very diverse origin. High levels of PAI-1 are associated 
with worse prognosis in patients with breast can­
cer69,89, gastric cancer74, various forms of lung can­
cer155 and in cervical cancer100. Furthermore, higher 
levels of PAI-1 in cancer tissue compared to benign 
or normal tissue is encountered in colorectum61,201 
and the brain110. PAI-1 mRNA has been localized in 
endothelial cells167 in the tumour surrounding stro­
ma, but also in colorectal cancer cells215, in endothelial 
cells and tumour cells of brain tumours23,104,234, and in 
breast cancer cells10,90, 179. In melanomas, however, 
both in nude mouse xenografts of PAI-1 positive tu­
mour cells and in human tumours, we found that tu­
mour cells make the mRNA, but that the protein is 
deposited in the extracellular matrix44,45 (and see 
Fig. 3e-h). Extracellular matrix staining was also ob­
served in breast cancer10.
PAI-2 in Human Tumours
At least in some tumours, the presence of PAI-2 is 
beneficiary for the patient’s survival. Higher levels of 
PAI-2 is associated with good prognosis in breast can­
cer15,58,210. Similar tendencies exist for gastric can­
cer139, squamous cell carcinoma66,138, pancreatic 
cancer212 and ovarian cancer166, although high levels 
of PAI-2 have been found in the tumour cystic fluid 
and in peritoneal fluid of ovarian cancer pa­
tients24, 25,30.
In some tumours however, elevated levels of PAI-2 
are associated with progression of the disease. In­
creased PAI-2 is seen in colon cancer compared to co­
lon adenomas and normal mucosa198, and is associated 
with poor survival in these patients61. Incidentally, PAI-
2 maps to a chromosomal region which is deleted in 
70% of colon cancer cases . Gliomas exhibit in­
creased levels of u-PA and PAI-1, but hardly any 
PAI-2 is found in glioma extracts110. In cutaneous mel­
anoma, we found PAI-2 only in advanced primary tu­
mours and metastases44, and in uveal melanoma, PAI-2 
was only present in lesions with poor prognosis45. PAI-
2 is mainly localized in tumour cells in all malignancies 
studied by immunohistochemistry.
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Concluding Remarks
In the last five years, the presence and localization of 
components of the plasminogen activation system has 
been well documented for a large group of tumours. In 
order to clarify mechanisms of plasminogen activation 
in tumours of diverse origin, consensus is needed on the 
exact localization of the proteins. Therefore, the con­
troversies regarding the localization of the various 
components have to be cleared. Since the staining en­
countered in the tissue sections can be diagnostically 
relevant, it is important that the applied staining pro­
cedures are reproducible. Furthermore, complemen­
tary techniques should be used to confirm the 
results. Additional studies on the functional state of 
components of the plasminogen activation system in 
the tissue sections would be of interest. Antibodies 
which discriminate between inactive free pro-u-PA, ac­
tive u-PA bound to its receptor, u-PA inactivated by 
PAI, etc. might elucidate the mechanism of plasmino­
gen activation in tumour tissue.
Whether modulation of the plasminogen activation 
system can indeed be applied in human tumour ther­
apy remains to be seen. Knock-out mice lacking both 
t-PA and u-PA and knock-out mice lacking PAI-1 are 
viable, healthy and capable of sexual reproduc­
tion26,27. Apparently, back-up mechanisms exist for 
physiological processes like wound healing, fibrinoly­
sis and embryo-implantation. In analogy, one can en­
visage that under plasminogen activation blocked 
conditions other proteases might be used by the cells 
to invade and metastasize. Nonetheless, knowledge 
of the PA status of a tumour may become useful in 
choosing the more effective therapeutic strategy57*59.
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